Ontology highlight
ABSTRACT:
SUBMITTER: Rajbhandari N
PROVIDER: S-EPMC5369772 | biostudies-literature | 2017 Feb
REPOSITORIES: biostudies-literature
Rajbhandari Nirakar N Lin Wan-Chi WC Wehde Barbara L BL Triplett Aleata A AA Wagner Kay-Uwe KU
Cell reports 20170201 9
Mutant KRAS and c-MYC are oncogenic drivers and rational therapeutic targets for the treatment of pancreatic cancer. Although tumor growth and homeostasis are largely dependent on these oncogenes, a few residual cancer cells are able to survive the ablation of mutant KRAS and c-MYC. By performing a genome-wide gene expression analysis of in vivo-derived bulk tumor cells and residual cancer cells lacking the expression of mutant KRAS or c-MYC, we have identified an increase in autocrine IGF1/AKT ...[more]